Analysis of interleukin-10 promoter single nucleotide polymorphisms and risk of non-Hodgkin lymphoma in a Malaysian population

Leukemia and Lymphoma

Volumn 56, Issue 1, 2015, Pages 163-168

  Lim, Yat Yuen ^a   Chin, Yoon Ming ^a   Tai, Mei Chee ^a   Fani, Somayeh ^a   Chang, Kian Meng ^b   Ong, Tee Chuan ^b   Bee, Ping Chong ^c   Gan, Gin Gin ^c   Ng, Ching Ching ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b Hospital Ampang   (Malaysia)

^c UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

Genetic susceptibility; IL10; NHL; SNP

Indexed keywords

INTERLEUKIN 10;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CASE CONTROL STUDY; FEMALE; GENETIC PREDISPOSITION; GENETICS; HUMAN; MALAYSIA; MALE; MIDDLE AGED; NONHODGKIN LYMPHOMA; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERLEUKIN-10; LYMPHOMA, NON-HODGKIN; MALAYSIA; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC;

EID: 84922368089     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.907895     Document Type: Article

References (56)

1. Evans LS, Hancock BW. Non-Hodgkin lymphoma. Lancet 2003; 362:139-146.
2. Arifn OZ, Saleha ITN. NCR report 2007. Malaysia: Ministry of Health; 2011.
3. Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. Lancet 2012;380:848-857.
4. Saraiva M, O'Garra A. Te regulation of IL-10 production by immune cells. Nat Rev Immunol 2010;10:170-181.
5. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005;5:263-274.
6. Khatri VP, Caligiuri MA. A review of the association between interleukin-10 and human B-cell malignancies. Cancer Immunol Immunother 1998;46:239-244.
7. Hofmann SR ER, Zhou YJ, et al. Cytokines and their role in lymphoid development, diferentiation and homeostasis. Curr Opin Allergy Clin Immunol 2002;2:495-506.
8. MacNeil IA, Suda T, Moore KW, et al. IL-10, a novel growth cofactor for mature and immature T cells. J Immunol 1990;145:4167-4173.
9. Rousset F, Garcia E, Defrance T, et al. Interleukin 10 is a potent growth and diferentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA 1992;89:1890-1893.
10. Go NF, Castle BE, Barrett R, et al. Interleukin 10, a novel B cell stimulatory factor: unresponsiveness of X chromosome-linked immunodefciency B cells. J Exp Med 1990;172:1625-1631.
11. Voorzanger N, Touitou R, Garcia E, et al. Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors. Cancer Res 1996;56:5499-5505.
12. Inagaki A, Ishida T, Ishii T, et al. Clinical signifcance of serum T1-, T2-and regulatory T cells-associated cytokines in adult T-cell leukemia/lymphoma: high interleukin-5 and-10 levels are signifcant unfavorable prognostic factors. Int J Cancer 2006;118:3054-3061.
13. Blay JY, Burdin N, Rousset F, et al. Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. Blood 1993;82:2169-2174.
14. Lech-Maranda E, Bienvenu J, Michallet AS, et al. Elevated IL-10 plasma levels correlate with poor prognosis in difuse large B-cell lymphoma. Eur Cytokine Netw 2006;17:60-66.
15. el-Far M, Fouda M, Yahya R, et al. Serum IL-10 and IL-6 levels at diagnosis as independent predictors of outcome in non-Hodgkin's lymphoma. J Physiol Biochem 2004; 60: 253-258.
16. Stasi R, Zinzani PL, Galieni P, et al. Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin's lymphoma. Br J Haematol 1994;88:770-777.
17. Czarneski J, Lin YC, Chong S, et al. Studies in NZB IL-10 knockout mice of the requirement of IL-10 for progression of B-cell lymphoma. Leukemia 2004;18:597-606.
18. Mocellin S, Marincola FM, Young HA. Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol 2005;78:1043-1051.
19. Cervenak L, Morbidelli L, Donati D, et al. Abolished angiogenicity and tumorigenicity of Burkitt lymphoma by interleukin-10. Blood 2000;96:2568-2573.
20. Costeas PA, Koumas L, Koumouli A, et al. Cytokine polymorphism frequencies in the Greek Cypriot population. Eur J Immunogenet 2003;30:341-343.
21. Lan Q, Zheng T, Rothman N, et al. Cytokine polymorphisms in the T1/T2 pathway and susceptibility to non-Hodgkin lymphoma. Blood 2006;107:4101-4108.
22. Rothman N, Skibola C F, Wang SS, et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol 2006;7:27-38.
23. Breen EC, Boscardin WJ, Detels R, et al. Non-Hodgkin's B cell lymphoma in persons with acquired immunodefciency syndrome is associated with increased serum levels of IL10, or the IL10 promoter -592 C/C genotype. Clin Immunol 2003;109:119-129.
24. Purdue MP, Lan Q, Kricker A, et al. Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: fndings from the New South Wales non-Hodgkin Lymphoma Study. Carcinogenesis 2007;28:704-712.
25. Minnicelli C, Barros MH, Klumb CE, et al. Relationship of Epstein-Barr virus and interleukin 10 promoter polymorphisms with the risk and clinical outcome of childhood Burkitt lymphoma. PLoS One 2012;7:e46005.
26. Gibson AW, Edberg JC, Wu J, et al. Novel single nucleotide polymorphisms in the distal IL-10 promoter afect IL-10 production and enhance the risk of systemic lupus erythematosus. J Immunol 2001;166:3915-3922.
27. Salhi A, Rodrigues V Jr, Santoro F, et al. Immunological and genetic evidence for a crucial role of IL-10 in cutaneous lesions in humans infected with Leishmania braziliensis. J Immunol 2008;180:6139-6148.
28. Sun F, Sun Y, Zhang D, et al. Association of interleukin-10 gene polymorphism with cachexia in Chinese patients with gastric cancer. Ann Clin Lab Sci 2010;40:149-155.
29. Turner DM, Williams DM, Sankaran D, et al. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997;24:1-8.
30. Eskdale J, Keijsers V, Huizinga T, et al. Microsatellite alleles and single nucleotide polymorphisms (SNP) combine to form four major haplotype families at the human interleukin-10 (IL-10) locus. Genes Immun 1999;1:151-155.
31. Zeng L, Gu W, Chen K, et al. Clinical relevance of the interleukin 10 promoter polymorphisms in Chinese Han patients with major trauma: genetic association studies. Crit Care 2009;13:R188.
32. Crawley E, Kay R, Sillibourne J, et al. Polymorphic haplotypes of the interleukin-10 5' fanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum 1999;42:1101-1108.
33. Bogunia-Kubik K, Mazur G, Wrobel T, et al. Interleukin-10 gene polymorphisms infuence the clinical course of non-Hodgkin's lymphoma. Tissue Antigens 2008;71:146-150.
34. Lee JJ, Kim DH, Lee NY, et al. Interleukin-10 gene polymorphism infuences the prognosis of T-cell non-Hodgkin lymphomas. Br J Haematol 2007;137:329-336.
35. Levy Y, Brouet JC. Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein. J Clin Invest 1994;93:424-428.
36. Alas S, Emmanouilides C, Bonavida B. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 2001;7:709-723.
37. Cohen SB, Crawley JB, Kahan MC, et al. Interleukin-10 rescues T cells from apoptotic cell death: association with an upregulation of Bcl-2. Immunology 1997;92:1-5.
38. Gupta M, Han JJ, Stenson M, et al. Elevated serum IL-10 levels in difuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation. Blood 2012;119:2844-2853.
39. Slack GW, Gascoyne RD. MYC and aggressive B-cell lymphomas. Adv Anat Pathol 2011;18:219-228.
40. Howell WM, Rose-Zerilli MJ. Interleukin-10 polymorphisms, cancer susceptibility and prognosis. Fam Cancer 2006;5:143-149.
41. Meenagh A, Williams F, Ross OA, et al. Frequency of cytokine polymorphisms in populations from western Europe, Africa, Asia, the Middle East and South America. Hum Immunol 2002;63: 1055-1061.
42. Mok CC, Lanchbury JS, Chan DW, et al. Interleukin-10 promoter polymorphisms in Southern Chinese patients with systemic lupus erythematosus. Arthritis Rheum 1998;41:1090-1095.
43. Hofmann SC, Stanley EM, Cox ED, et al. Ethnicity greatly infuences cytokine gene polymorphism distribution. Am J Transplant 2002;2:560-567.
44. Padyukov L, Hahn-Zoric M, Lau YL, et al. Diferent allelic frequencies of several cytokine genes in Hong Kong Chinese and Swedish Caucasians. Genes Immun 2001;2:280-283.
45. Weiss KM, Terwilliger JD. How many diseases does it take to map a gene with SNPs? Nat Genet 2000;26:151-157.
46. Syvanen AC. Accessing genetic variation: genotyping single nucleotide polymorphisms. Nat Rev Genet 2001;2:930-942.
47. Reuss E, Fimmers R, Kruger A, et al. Diferential regulation of interleukin-10 production by genetic and environmental factors-a twin study. Genes Immun 2002;3:407-413.
48. Moraes MO, Santos AR, Schonkeren JJ, et al. Interleukin-10 promoter haplotypes are diferently distributed in the Brazilian versus the Dutch population. Immunogenetics 2003;54:896-899.
49. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007;81:559-575.
50. Muller AM, Ihorst G, Mertelsmann R, et al. Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology. Ann Hematol 2005;84:1-12.
51. Hosgood HD 3rd, Au WY, Kim HN, et al. IL10 and TNF variants and risk of non-Hodgkin lymphoma among three Asian populations. Int J Hematol 2013;97:793-799.
52. Wong HL, Breen EC, Pfeifer RM, et al. Cytokine signaling pathway polymorphisms and AIDS-related non-Hodgkin lymphoma risk in the multicenter AIDS cohort study. AIDS 2010;24:1025-1033.
53. Cao HY, Zou P, Zhou H. Genetic association of interleukin-10 promoter polymorphisms and susceptibility to difuse large B-cell lymphoma: a meta-analysis. Gene 2013;519:288-294.
54. Westendorp RG, Langermans JA, Huizinga TW, et al. Genetic infuence on cytokine production and fatal meningococcal disease. Lancet 1997;349:170-173.
55. Grondal G, Kristjansdottir H, Gunnlaugsdottir B, et al. Increased number of interleukin-10-producing cells in systemic lupus erythematosus patients and their first-degree relatives and spouses in Icelandic multicase families. Arthritis Rheum 1999; 42:1649-1654.
56. Lech-Maranda E, Baseggio L, Bienvenu J, et al. Interleukin-10 gene promoter polymorphisms infuence the clinical outcome of difuse large B-cell lymphoma. Blood 2004;103:3529-3534.